Recently, a preclinical study by Gonzalez-Martinez and colleagues [116] investigated the therapeutic potential of peptide-conjugated antimiRs in treating DM1 by enhancing the expression of MBNL1, a protein sequestered by toxic RNA in DM1. The gene discussed is MBNL1; the disease is myotonic dystrophy type 1.